Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)
- 1 January 2006
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 95 (03) , 585-586
- https://doi.org/10.1160/TH05-09-0620
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic strokeJournal of Thrombosis and Haemostasis, 2005
- Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefactThrombosis and Haemostasis, 2005
- Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolismBlood, 2004
- Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assaysBritish Journal of Haematology, 2004
- Development of a Genotype 325–Specific proCPU/TAFI ELISAArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of EuropeArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlledBlood, 2001
- Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosisBlood, 2000